Skip to main content
. 2019 Nov 29;9:1295. doi: 10.3389/fonc.2019.01295

Figure 2.

Figure 2

KRAS MAFs and the detection rate for PC in different clinical stages. (A,B) Correlation of KRAS MAF in ctDNA and tumor tissue with PC stages. (C) PC detection rate by tissue, ctDNA, CA19-9, and the combined assay of ctDNA and CA19-9. *p < 0.05; ***p < 0.001; NS, not significant.